CD80 Protein (CD80) (AA 35-242) (Fc Tag)
-
- Antigène Voir toutes CD80 Protéines
- CD80
- Type de proteíne
- Recombinant
- Attributs du protein
- AA 35-242
-
Origine
- Humain
-
Source
- CHO Cells
- Purification/Conjugué
- Cette CD80 protéine est marqué à la Fc Tag.
- Fonction
- CD80 (human):Fc (mouse) (rec.)
- Specificité
- The extracellular domain of human CD80 (aa 35-242) is fused to the N-terminus of the Fc region of mouse IgG2a.
- Attributs du produit
- Protein. The extracellular domain of human CD80 (aa 35-242) is fused to the N-terminus of the Fc region of mouse IgG2a. Source: CHO cells. Endotoxin content: <0.06EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.
- Pureté
- >98 % (SDS-PAGE)
- niveau d'endotoxine
- <0.06EU/μg protein (LAL test, Lonza).
- Biological Activity Comment
- Measured by its ability to induce IL-2 secretion by Jurkat human acute T cell leukemia cells.
- Top Product
- Discover our top product CD80 Protéine
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Concentration
- Lot specific
- Buffer
- Lyophilized from 0.2μm-filtered solution in PBS.
- Conseil sur la manipulation
- Avoid freeze/thaw cycles.
- Stock
- 4 °C,-20 °C
- Stockage commentaire
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
-
- Antigène
- CD80
- Autre désignation
- CD80 (CD80 Produits)
- Synonymes
- B7 Protein, B7-1 Protein, B7.1 Protein, BB1 Protein, CD28LG Protein, CD28LG1 Protein, LAB7 Protein, B71 Protein, Cd28l Protein, Ly-53 Protein, Ly53 Protein, MIC17 Protein, TSA1 Protein, CD80 molecule Protein, Cd80 molecule Protein, CD80 antigen Protein, CD80 Protein, Cd80 Protein
- Sujet
-
Alternate Names/Synonyms: B7-1
Product Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.
- NCBI Accession
- NP_005182
- Pathways
- TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
-